Pharma Unscripted

Pharma Unscripted

By RTI Health SolutionsScienceTechnologyLife Sciences
Download on the App Store

All Pharma Unscripted episodes

  • Fit-for-Purpose: Turning EHR Data into Real-World Evidence

    What makes real-world data fit for your study?

    A large patient population does not guarantee that a dataset can answer your research question. This episode explores how study design, clinical detail, data provenance, and patient perspectives shape the evidence a source can support—and what teams should assess before committing to it.

    Sean Candrilli of RTI Health Solutions and Jeff Graham of BEKhealth join host Peter Wirth to discuss evaluating data fitness, uncovering context within electronic health records, and connecting scientific requirements with data feasibility.

    Key Topics

    • Matching data sources to the research question and intended use
    • Clinical variables, follow-up, and data provenance
    • What clinical notes reveal about treatment changes
    • Patient perspectives that complement electronic health records
    • Early collaboration between researchers and data partners

    CONTINUE EXPLORING
    Read the companion article: Fit-for-Purpose Real-World Data: Why Patient Counts Aren’t Enough

    20 min
  • JCA for Vaccines: Preparing Today for 2030

    How can vaccine manufacturers prepare for EU JCA in 2030?

    Vaccines are expected to enter the EU Joint Clinical Assessment (JCA) framework in 2030, but evidence decisions are being made now. This episode explores why vaccines pose distinct assessment challenges, where clinical development may leave comparative evidence gaps, and how manufacturers can begin preparing while vaccine-specific expectations continue to evolve.

    Sandra Talbird and Lacey Lopez join host Peter Wirth to discuss early evidence planning, scientific consultation, and the connection between EU assessment and national vaccine decisions.

    Key Topics
    • EU JCA for vaccines and the 2030 timeline
    • Comparative evidence gaps and duration of protection
    • Real-world evidence, modeling, and indirect comparisons
    • Joint scientific consultation and national vaccine decisions
    • Early evidence planning and alignment across teams
    Continue Exploring Vaccine Evidence Planning

    Read the companion article, “Preparing Vaccine Evidence for EU JCA in 2030,” for practical priorities to guide your next evidence planning discussion.

    16 min
  • Delphi Methodology: Turning Expert Judgment into Actionable Evidence
    How can Delphi studies address critical evidence gaps?

    When traditional evidence is limited or unavailable, Delphi methodology offers a structured way to turn expert judgment into credible, actionable insights.

    In this episode, Ash Menon and Mark Price discuss when to use Delphi research, what rigorous study design looks like, and how findings can support publications, regulatory submissions, HTA, and market access strategy.


    Key Topics

    • When Delphi methodology is appropriate
    • Panel and questionnaire design
    • Consensus thresholds and iterative rounds
    • CREDES and ACCORD reporting standards
    • Regulatory, HTA, and market access applications
    Continue Exploring Delphi Methodology

    Get a practical, step-by-step approach to designing, conducting, analyzing, and reporting a rigorous Delphi study.

    Download the Delphi methodology guide

    26 min
  • The First EU JCA Report: Methodological Learnings and Implications for Future Submissions

    What can manufacturers learn from the first EU JCA report?

    The first EU Joint Clinical Assessment report offers an early look at how evidence may be evaluated under the EU HTA Regulation. This episode explores key methodological learnings from the tovorafenib assessment and what they may mean for future submissions, especially in rare diseases.

    Key Topics:
    • PICO scope and consolidation
    • Systematic literature review expectations
    • Indirect treatment comparisons
    • Single-arm evidence in orphan diseases
    • Future JCA submission planning

    Guests:
    • Caroline Ling, Vice President, Health Outcomes – Europe
    • Vijay D’Souza, Associate Director, European Value and Access

    24 min
  • The Patient Experience: Evaluating Tolerability in Oncology Treatments

    Why is patient-centered evidence critical in oncology?

     

    As oncology treatments become more targeted and long-term, organizations need evidence that captures real-world patient experience. This episode explores how PROs, tolerability, and patient-centered evidence are shaping adherence, evidence strategy, and market access.

     

    Key Topics:

    • Real-world patient experience
    • Tolerability and treatment burden
    • Patient-reported outcomes (PROs)
    • Patient-centered evidence strategy
    • Adherence and market access

     

    Guests:

    • Ari Gnanasakthy, Principal Scientist, Patient-Centered Outcomes Assessment
    • Dawn Odom, Vice President, Biostatistics

     

    Learn more about tolerability research

    27 min
  • AI in Medical Communications: Why Human Expertise Still Matters

    This episode is part three of a three-part series featured on Fierce Pharma’s The Top Line podcast.

    AI is transforming medical communications, but it’s not replacing human expertise.

    In this episode of Pharma Unscripted, we explore how AI is being used across med comms workflows, from literature review to content creation, and where it introduces risk.

    Accuracy, context, and scientific integrity remain critical, making human oversight essential in an AI-driven environment.

    Key Topics:

    • AI in medical communications
    • Scientific accuracy and governance
    • Risks and limitations of AI-generated content
    • Role of human expertise

    Guests:

    • Margaret Mathes, Director of Medical Editing
    • Gabby Dardis, Senior Integrated Evidence Strategist
    • Frances Ramsey, Manager of Library Services
    21 min
  • From Approval to Value: Evidence Storytelling, HEOR & Market Access

    This episode is part two of a three-part series featured on Fierce Pharma’s The Top Line podcast.

    Getting a therapy approved is only part of the journey, demonstrating its value is what drives access.

    In this episode of Pharma Unscripted, we explore how evidence storytelling is becoming critical in biopharma. From real-world evidence (RWE) to health economics and outcomes research (HEOR), organizations must translate complex data into clear, decision-relevant insights.

    As payers and HTA bodies demand stronger value demonstration, how you communicate evidence can directly impact patient access.

    Key Topics:

    • Evidence storytelling in biopharma
    • HEOR and real-world evidence (RWE)
    • Value communication for payers and HTAs
    • Market access strategy

    Guests:

    • Kate Lothman, Director of Medical Writing & Publications
    • Sara Musetti Jenkins, Principal Medical Writer
    • Jason Crouch, Graphic Designer
    18 min
  • Putting Patients First: Patient-Centered Evidence & PROs in Biopharma

    This episode is part one of a three-part series featured on Fierce Pharma’s The Top Line podcast.

    What does it really mean to put patients first in biopharma?

    In this episode of Pharma Unscripted, we explore how patient-centered evidence, including patient-reported outcomes (PROs), is reshaping clinical development, regulatory expectations, and market access.

    As decision-makers look beyond traditional endpoints, understanding the real patient experience, quality of life, treatment burden, and daily impact, is becoming essential.

    Key Topics:

    • Patient-reported outcomes (PROs)
    • Patient-centered evidence generation
    • Clinical trial design and endpoints
    • Market access and patient experience

    Guests:

    • Ash Menon, Sr. Medical Affairs Lead
    • Mark Price, Head of Expert Perspectives
    29 min